Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
2.
Curr Neurol Neurosci Rep ; 12(6): 642-54, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22991069

RESUMO

Though well-known as a cause of liver disease, Hepatitis C virus infection is emerging as a cause of a variety of peripheral and central nervous system disorders. The virus causes chronic persistent infection with complex immune responses in the majority of individuals. Viral infection may have the potential to generate neurological illness through direct infection of neural cells or through immune-mediated mechanisms, including enhancement of autoimmune responses. Moreover, the mainstay of antiviral treatment of hepatitis C infection, interferon-alpha, is itself associated with neurological morbidity. Thus neurologists are increasingly faced with diagnosing or even predicting a wide spectrum of neurological complications of hepatitis C infection and/or its treatment.


Assuntos
Antivirais/efeitos adversos , Hepatite C/complicações , Doenças do Sistema Nervoso/complicações , Antivirais/uso terapêutico , Hepatite C/tratamento farmacológico , Hepatite C/imunologia , Hepatite C/virologia , Humanos , Interferon-alfa/efeitos adversos , Interferon-alfa/uso terapêutico , Doenças do Sistema Nervoso/induzido quimicamente , Doenças do Sistema Nervoso/tratamento farmacológico , Doenças do Sistema Nervoso/imunologia , Doenças do Sistema Nervoso/virologia
8.
Mult Scler Relat Disord ; 1(3): 148-51, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25877082

RESUMO

Interferon (IFN)-ß is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-ß (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-ß-1a 3 times weekly and review the previously published cases.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA